{"transactions":[{"id":2068772,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":121037,"kind":"person","name":"Rabinowitz Michael","position":1,"cik":"0001876182","reported_name":"Rabinowitz Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-04T12:24:13.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":11900,"price":12.4917,"value":148651.23,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.01 to $13.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range."}],"balance_after":126143,"source":{"system":"sec-edgar","filing":"0001209191-23-000517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919123000517/doc4.xml","form_type":"4"}},{"id":2068771,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":121037,"kind":"person","name":"Rabinowitz Michael","position":1,"cik":"0001876182","reported_name":"Rabinowitz Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-04T12:24:13.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":1425,"price":13.0132,"value":18543.81,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022."}],"balance_after":138043,"source":{"system":"sec-edgar","filing":"0001209191-23-000517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919123000517/doc4.xml","form_type":"4"}},{"id":2199210,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":121037,"kind":"person","name":"Rabinowitz Michael","position":1,"cik":"0001876182","reported_name":"Rabinowitz Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-08-02T00:00:30.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":139468,"source":{"system":"sec-edgar","filing":"0001209191-22-043764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919122043764/doc4.xml","form_type":"4"}}]}